Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoids versus placebo for acute exacerbation of idiopathic pulmonary fibrosis
2022-002464-75Phase 2Active
- Sponsor
- Groupe hospitalier Paris Saint-Joseph
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Glucocorticoids with Placebo (2 arms). Primary endpoint: All-cause mortality at Day 30. Started Dec 2022; status: active.
02
Drugs
prednisonemethylprednisolone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2022-002464-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002464-75.